Rodman & Renshaw initiated coverage on Nkarta with a new price target
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Outperform → Mkt Perform | William Blair | |
| 10/9/2024 | $14.00 | Buy | Rodman & Renshaw |
| 8/14/2024 | $16.00 | Outperform → Strong Buy | Raymond James |
| 3/22/2024 | $13.00 → $16.00 | Strong Buy → Outperform | Raymond James |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 10/10/2022 | $25.00 | Buy | Canaccord Genuity |
| 7/28/2022 | $26.00 | Buy | Needham |
| 7/18/2022 | $30.00 | Outperform | SVB Leerink |
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)